🔗 Permalink

Inventor profile of:

Benjamin Rossi

City:

Marseille

Country:

France

Published Applications:

Last publication date:

2025-09-25

Top Assignees for applications by Benjamin Rossi

The entities that hold a legal rights for patent applications filed by inventor Rossi Benjamin:

INNATE PHARMA 20 Marseilles, France
OREGA BIOTECH 2 Ecully, France
Innate Pharma 2 Marseille, France
UNIVERSITE DE LA MEDITERRANEE 1 MARSEILLE CEDEX 07, France
Innate Pharma SA 1 Marseille, France
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 1 PARIS CEDEX 13, France

Recent patent applications by Rossi Benjamin

Benjamin Rossi from Marseille, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-09-25

US20250297004A1

Chemistry; metallurgy

NECTIN-4 BINDING AGENTS

#2 | 2025-07-24

US20250236678A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATING CANCER

#3 | 2025-07-03

US20250215107A1

Chemistry; metallurgy

MULTISPECIFIC NK ENGAGER PROTEIN

#4 | 2025-01-02

US20250002601A1

Chemistry; metallurgy

MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2

#5 | 2024-10-03

US20240325557A1

Human necessities

TREATMENT OF CANCER

#6 | 2024-09-05

US20240294634A1

Chemistry; metallurgy

TREATMENT OF CANCER WITH ILT-2 INHIBITORS

#7 | 2024-05-30

US20240174748A1

Chemistry; metallurgy

VARIABLE REGIONS FOR NKP46 BINDING PROTEINS

#8 | 2024-05-02

US20240141042A1

Chemistry; metallurgy

MULTISPECIFIC NKp46 BINDING PROTEINS

#9 | 2024-04-18

US20240124579A1

Chemistry; metallurgy

KIR3DL2 BINDING AGENTS

#10 | 2024-04-11

US20240117042A1

Chemistry; metallurgy

IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS

#11 | 2023-10-26

US20230340143A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATING CANCER

#12 | 2023-03-30

US20230099801A1

Chemistry; metallurgy

RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS

#13 | 2023-03-23

US20230085847A1

Chemistry; metallurgy

COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER

#14 | 2023-01-26

US20230025732A1

Chemistry; metallurgy

Nucleic acids encoding and methods of producing proteins comprising antibody chains

#15 | 2022-07-07

US20220213202A1

Chemistry; metallurgy

Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123

#16 | 2022-05-05

US20220135676A1

Chemistry; metallurgy

MULTISPECIFIC ANTIGEN BINDING PROTEINS

#17 | 2022-01-27

US20220025056A1

Chemistry; metallurgy

LEUCOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR NEUTRALIZING ANTIBODIES

#18 | 2022-01-27

US20220025045A1

Chemistry; metallurgy

COMPOUNDS AND METHODS FOR TREATMENT OF HEAD AND NECK CANCER

#19 | 2021-11-25

US20210363249A1

Chemistry; metallurgy

SIGLEC NEUTRALIZING ANTIBODIES

#20 | 2021-09-02

US20210269523A1

Chemistry; metallurgy

Variable regions for NKp46 binding proteins

#21 | 2020-11-26

US20200369765A1

Chemistry; metallurgy

Siglec-9-neutralizing antibodies

#22 | 2020-11-26

US20200369764A1

Chemistry; metallurgy

Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer

#23 | 2020-06-25

US20200199228A1

Chemistry; metallurgy

KIR3DL2 binding agents

#24 | 2020-04-30

US20200131268A1

Chemistry; metallurgy

NKp46 binding proteins

#25 | 2020-02-13

US20200048345A1

Chemistry; metallurgy

MULTISPECIFIC ANTIGEN BINDING PROTEINS

#26 | 2020-01-23

US20200024357A1

Chemistry; metallurgy

Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide

#27 | 2019-12-26

US20190389961A1

Chemistry; metallurgy

Compositions and methods for treating cancer

#28 | 2019-07-18

US20190218308A1

Chemistry; metallurgy

RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS

#29 | 2019-07-18

US20190218304A1

Chemistry; metallurgy

POTENTIATING THE EFFECT OF ATP RELEASE

#30 | 2019-03-21

US20190085077A1

Chemistry; metallurgy

Siglec neutralizing antibodies

#31 | 2019-02-21

US20190055315A1

Chemistry; metallurgy

Multispecific NK engager protein

#32 | 2019-02-14

US20190048093A1

Chemistry; metallurgy

Multispecific NK engager protein

#33 | 2018-12-13

US20180355036A1

Chemistry; metallurgy

Variable regions for NKp46 binding proteins

#34 | 2018-12-06

US20180344829A1

Human necessities

Siglec-10 antibodies

#35 | 2017-10-26

US20170306014A1

Chemistry; metallurgy

CROSS REACTIVE SIGLEC ANTIBODIES

#36 | 2017-07-27

US20170210802A1

Chemistry; metallurgy

Multispecific antigen binding proteins

#37 | 2017-07-13

US20170198038A1

Chemistry; metallurgy

NKp46 binding proteins

#38 | 2016-12-22

US20160369002A1

Chemistry; metallurgy

Multispecific NK engager proteins

#39 | 2016-02-18

US20160046713A1

Chemistry; metallurgy

Anti-KIR3D antibodies

#40 | 2015-10-15

US20150291692A1

Chemistry; metallurgy

KIR3DL2 binding agents

#41 | 2015-08-20

US20150232556A1

Chemistry; metallurgy

KIR3DL2 binding agents

#42 | 2014-03-06

US20140065154A1

Human necessities

TLR3 BINDING AGENTS

#43 | 2012-03-15

US20120064081A1

Chemistry; metallurgy

Anti-KIR3D antibodies

#44 | 2010-05-20

US20100124555A1

Chemistry; metallurgy

Compositions and Methods for Treating Pancreatic Tumors

InventorID:

676092 ⎘